



April 16, 2025

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**BSE Limited**

P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
Mumbai - 400 001

**Symbol: LUPIN**

**Scrip Code: Equity - 500257**

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") – Litigation/Dispute**

Pursuant to Regulation 30 read with Schedule III of the Listing Regulations, we hereby inform that United States District Court for the District of Delaware has passed an order in the matter of Myrbetriq® patent case.

The detailed disclosures as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and other applicable circulars, in respect of aforesaid matter is enclosed herewith as Annexure I.

**For LUPIN LIMITED**

**AMIT KUMAR GUPTA  
COMPANY SECRETARY & COMPLIANCE OFFICER  
(ACS -15754)**

Encl: a/a.

LUPIN LIMITED

**Registered Office:** 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)



## Annexure I

**Disclosure as per Regulation 30 of Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and other applicable circulars issued in this regard.**

Sr. No.	Particulars	Details
1.	Name(s) of the opposing party	Astellas Pharma Inc.
2.	Court / tribunal /agency where litigation is filed	United States District Court for the District of Delaware ('Court')
3.	Brief details of dispute/litigation	<p>In respect of Lupin's generic products 'Mirabegron', Astellas Pharma had filed a patent infringement case against Lupin.</p> <p>On April 15, 2025, the Court ruled in favor of Astellas Pharma regarding the validity of its U.S. Patent No. 10,842,780 ("the '780 patent"). The Court noted that the issues of whether Lupin's products infringe the '780 patent, damages, and any additional invalidity theories will be litigated at a consolidated jury trial in 2026.</p>
4.	Expected financial implications on the Company, if any	As on now, based on the Court Order, there are no material financial implications. The Company believes it has a strong case and is evaluating further legal action in the matter.
5.	Quantum of claims, if any.	None as on date.

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)